AstraZeneca’s Forxiga drug has been recommended for approval in the EU for symptomatic chronic heart failure, the pharma company said on Monday.
If approved, Forxiga will be the first heart failure therapy indicated across the full ejection fraction range – which measures how much blood the left ventricle of the heart pumps out every heartbeat – with proven mortality reduction, it added.
Mene Pangalos, executive vice-president of biopharmaceuticals research and development, said: “Forxiga has already transformed the standard of care for millions of people in the EU living with heart failure. If approved for this new, broader indication for heart failure with mildly reduced or preserved ejection fraction, more patients will be able to benefit from this well-tolerated and guideline-directed treatment.”
“As a leader in cardiorenal disease, AstraZeneca is committed to expanding heart failure treatment options, changing the way we treat this complex disease to improve patient outcomes.”
Reporting by Frank Prenesti for Sharecast.com
